Westport, Connecticut

BioSig Appoints Brenda Castrodad to Lead Human Resources

Retrieved on: 
Tuesday, February 16, 2021
Westport, Connecticut, Westport, CT Corporation

Westport, CT, Feb. 16, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it appointed Ms. Brenda Castrodad to lead its Human Resources department.

Key Points: 
  • Westport, CT, Feb. 16, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it appointed Ms. Brenda Castrodad to lead its Human Resources department.
  • We look forward to working with Brenda as we prepare the Company for commercial success, commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.
  • Im thrilled to be a valuable contributor to the incredible growth path ahead of us, commented Brenda Castrodad.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

Major Medical Centers Enter into Installation Agreements for Evaluation of BioSig PURE EP™ Systems

Retrieved on: 
Wednesday, February 10, 2021
Cornell University, NewYork–Presbyterian Healthcare System, Trauma centers, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Houston Methodist Hospital, Weill Cornell Medical Center, Westport, Connecticut, Ivy League, Hospitals, Health sciences

New installations of the PURE EP System will now follow a shorter assessment cycle of 90 days based on favorable data from installation evaluations in 2020.

Key Points: 
  • New installations of the PURE EP System will now follow a shorter assessment cycle of 90 days based on favorable data from installation evaluations in 2020.
  • New clinical sites due to receive BioSigs PURE EP System include New York-Presbyterian/Weill Cornell Medical Center, Michigan MedicineUniversity Hospital (two centers that account for two of the largest EP programs in the country), and Houston Methodist Hospital.
  • More than 500 patient cases have been conducted using the PURE EPSystem by 34 physicians in seven clinical sites to date.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig to Present at the 26th Annual International AF Symposium

Retrieved on: 
Friday, January 15, 2021
Westport, Connecticut

More than 470 patient cases have been conducted with the PURE EPTM System to date across seven clinical sites in the US.

Key Points: 
  • More than 470 patient cases have been conducted with the PURE EPTM System to date across seven clinical sites in the US.
  • Dr. Gallinghouse is one of the most experienced PURE EPTM physician users, having worked with the technology since 2019.
  • This year, the AF Symposium will be streamed live and can be attended free of charge.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig CEO Kenneth L. Londoner to Present at the Sidoti Winter 2021 Investor Conference

Retrieved on: 
Wednesday, January 6, 2021
Westport, Connecticut

During the presentation, Mr. Londoner will provide an overview of the Company and business highlights.

Key Points: 
  • During the presentation, Mr. Londoner will provide an overview of the Company and business highlights.
  • To date, more than 410 patient procedures have been conducted with the PURE EP System by more than 32 electrophysiologists across seven different clinical sites in the United States.
  • Investors and security holders are urged to read these documents free of charge on the SECs website at http://www.sec.gov.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota

Retrieved on: 
Friday, December 18, 2020
Westport, Connecticut, Wilton, Ballou, Westport

Under the terms of the agreement, the Company intends to launch a program to develop novel therapies to treat sympathetic nervous system disease.

Key Points: 
  • Under the terms of the agreement, the Company intends to launch a program to develop novel therapies to treat sympathetic nervous system disease.
  • We are very pleased to commence a new research and development program with the accomplished team at the University of Minnesota.
  • I am extremely excited about this strong collaboration between the University of Minnesota and NeuroClear Technologies.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig Achieves First Commercial Sale of Three PURE EP Systems

Retrieved on: 
Friday, December 11, 2020
Westport, Connecticut, St Davids

Our first commercial sale to St. Davids HealthCare is an important milestone as we proceed in expanding our installed base nationwide, said Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.

Key Points: 
  • Our first commercial sale to St. Davids HealthCare is an important milestone as we proceed in expanding our installed base nationwide, said Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.
  • This installation cements our valued relationship with St. Davids and adds to the traction we are gaining in the electrophysiology (EP) market.
  • BioSig installed the first PURE EP System at St. Davids Medical Center in November 2019.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig CEO Kenneth L. Londoner to Present at the 13th Annual LD Micro Main Event Conference

Retrieved on: 
Thursday, December 10, 2020
Westport, Connecticut, Westport

During the presentation, Mr. Londoner will provide an overview of the Company and business highlights.

Key Points: 
  • During the presentation, Mr. Londoner will provide an overview of the Company and business highlights.
  • To date, more than 400 patient procedures have been conducted with the PURE EP System by more than 25 electrophysiologists across six different clinical sites in the United States.
  • Investors and security holders are urged to read these documents free of charge on the SECs website at http://www.sec.gov.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig to Highlight PURE EP™ System at the Benzinga Global Small Cap Conference

Retrieved on: 
Thursday, December 3, 2020
Branches of biology, Medicine, Clinical medicine, Cardiac electrophysiology, Electrophysiology, EP, Electrocardiography, Westport, Connecticut

During the presentation, Mr. Londoner will provide an overview of the Company and its operational highlights of 2020, including the progress of its PURE EP System installations and its commercialization goals.

Key Points: 
  • During the presentation, Mr. Londoner will provide an overview of the Company and its operational highlights of 2020, including the progress of its PURE EP System installations and its commercialization goals.
  • To date, more than 350 clinical cases have been conducted with BioSig's PURE EP System by 25 electrophysiologists in six medical centers across the country.
  • The Company's first product, PURE EP (tm) System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig to Host Business Update Conference Call on November 18, 2020

Retrieved on: 
Thursday, November 12, 2020
Westport, Connecticut, Wilton, Connecticut, Geography of the United States

Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. will review highlights from the Company's third quarter of 2020 and discuss corporate initiatives, including ongoing PURE EP System installations and commercialization outlook.

Key Points: 
  • Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. will review highlights from the Company's third quarter of 2020 and discuss corporate initiatives, including ongoing PURE EP System installations and commercialization outlook.
  • A replay will be available for two weeks starting on November 18, 2020, at approximately 7:15 PM ET.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

BioSig Issues October 2020 Shareholder Update Letter

Retrieved on: 
Wednesday, October 28, 2020
Westport, Connecticut, European Society of Cardiology, Wilton, Connecticut, Geography of the United States

BioSig recently announced the acceptance of two manuscripts, including a study abstract featuring robust clinical data collected with the PURE EP System.

Key Points: 
  • BioSig recently announced the acceptance of two manuscripts, including a study abstract featuring robust clinical data collected with the PURE EP System.
  • The data were reviewed in a blinded, independent analysis and presented at the European Society of Cardiologys ESC Congress 2020.
  • In 2020, BioSig raised $39 million and, as of June 30, 2020, had $36.9 million in cash on its balance sheet, placing it in the strongest financial position of its corporate history.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133